ID   HT-1080 JH-1/FIX
AC   CVCL_XG90
SY   JH-1 / FIX
DR   cancercelllines; CVCL_XG90
DR   Wikidata; Q94304215
RX   Patent=US7361639;
CC   Group: Patented cell line.
CC   Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C200005.
CC   Population: Caucasian.
CC   Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 5382; IDH1; Simple; p.Arg132Cys (c.394C>T); ClinVar=VCV000375891; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous (from parent cell line).
CC   Transfected with: HGNC; 3551; F9.
CC   Transfected with: UniProtKB; P00552; Transposon Tn5 neo.
CC   Derived from site: In situ; Bone, pelvis, acetabulum; UBERON=UBERON_0001269.
DI   NCIt; C3043; Fibrosarcoma
DI   ORDO; Orphanet_2030; Fibrosarcoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0317 ! HT-1080
SX   Male
AG   35Y
CA   Cancer cell line
DT   Created: 06-09-19; Last updated: 05-10-23; Version: 11
//
RX   Patent=US7361639;
RA   Xia J.-H.;
RT   "Gene therapy agent for haemophilia B and its preparation method.";
RL   Patent number US7361639, 22-Apr-2008.
//